Link between liver fibrosis in MASLD, ASCVD varies by glycemic status
For patients with metabolic dysfunction-associated steatotic liver disease (MASLD), the association between liver fibrosis and atherosclerotic cardiovascular disease (ASCVD) varies with glycemic status, according to a study published in Hepatology Communications.
A recent study published in Hepatology Communications has revealed that the connection between liver fibrosis and atherosclerotic cardiovascular disease (ASCVD) among patients with metabolic dysfunction-associated steatotic liver disease (MASLD) varies depending on glycemic status. Jaehong Jeong, a doctor from Yonsei University College of Medicine in Seoul, South Korea, led a retrospective cohort study involving 6,519 MASLD patients to determine whether the severity of liver fibrosis, as assessed using recommended noninvasive methods, is linked to the development of ASCVD across different glycemic states.
The researchers analyzed a subset of 3,221 participants in a survival analysis cohort. They discovered that the risk of ASCVD increased with worsening glycemic status. When examining liver fibrosis severity and incident ASCVD over time, they found that the association varied based on glycemic status. Patients with prediabetes exhibited a higher risk for ASCVD in the highest fibrosis tier (adjusted subdistribution hazard ratio of 2.62), particularly among younger individuals.
In contrast, diabetes patients showed a higher overall incidence of ASCVD across all fibrosis tiers (15.2% to 18.5%), without any significant increase due to fibrosis severity.
These findings emphasize the need for a personalized approach to ASCVD risk assessment in MASLD patients. Liver fibrosis severity, when evaluated during MASLD assessment, could provide valuable additional clinical information, particularly in patients with prediabetes or younger individuals.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
